✦ LIBER ✦

P01-147 - Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder

✍ Scribed by M. Darghal

Book ID: 119570119
Publisher: Elsevier Science
Year: 2010
Tongue: French
Weight: 27 KB
Volume: 25
Category: Article
ISSN: 0924-9338
DOI: 10.1016/s0924-9338(10)70352-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P01-126 - Olanzapine augmentation for tr

P01-126 - Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder: a case report

✍ M. Darghal 📂 Article 📅 2010 🏛 Elsevier Science 🌐 French ⚖ 31 KB

Ondansetron Augmentation in Treatment-Re

Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

✍ Pallanti, Stefano; Bernardi, Silvia; Antonini, Sarah; Singh, Nikhilesh; Hollande 📂 Article 📅 2009 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 150 KB

P02-382 - Pregabalin augmentation in tre

P02-382 - Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder

✍ P. Oulis; I. Mourikis; G. Konstantakopoulos 📂 Article 📅 2011 🏛 Elsevier Science 🌐 French ⚖ 11 KB

Pindolol augmentation in treatment-resis

Pindolol augmentation in treatment-resistant panic disorder and obsessive-compulsive disorder

✍ J. Zohar; P.N. Dannon; Y. Sasson; S. Hirschmann; I. Iancu; L.J. Grunhaus 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Citalopram for treatment-resistant obses

Citalopram for treatment-resistant obsessive-compulsive disorder

✍ S. Pallanti; L. Quercioli; R.S. Paiva; L.M. Koran 📂 Article 📅 1999 🏛 Elsevier Science 🌐 French ⚖ 111 KB

Amisulpiride augmentation in treatment r

Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial

✍ Özmen Metin; Kemal Yazici; Senel Tot; Aylin Ertekin Yazici 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

## Abstract Despite the effectiveness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive–compulsive disorder (OCD), 40% to 60% of patients who receive an adequate treatment with these agents have significant persisting symptoms. Newer atypical antipsyc